

Amendments to the Claims
(Clean Version)

- E1
D1
5. (Thrice Amended) An immunogenic composition comprising,
- (a) an immunogenic peptide fragment of fibroblast growth factor wherein the immunogenic peptide consists of a heparin binding domain of fibroblast growth factor, and ^{WO}immunogenic fragments of said immunogenic peptide; and
 - (b) a pharmaceutically acceptable carrier.

- E1
D2
15. (Thrice Amended) An immunogenic composition comprising,
- (a) an immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment consists of a receptor binding domain of vascular endothelial growth factor, and ^{WO}immunogenic fragments of said immunogenic peptide
 - (b) wherein the immunogenic peptide fragment consists of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9; and
 - (c) a pharmaceutically acceptable carrier.

- E1
D3
25. (Thrice Amended) An immunogenic composition comprising,
- (a) an immunogenic peptide fragment of fibroblast growth factor and vascular endothelial growth factor, wherein the immunogenic peptide fragment of fibroblast growth factor consists of a heparin binding domain and ^{WO}immunogenic fragments of said immunogenic peptide, and wherein the immunogenic peptide fragment of vascular endothelial growth factor consists of a receptor binding domain and ^{WO}immunogenic fragments of said immunogenic peptide; and

E1
D3

(b) a pharmaceutically acceptable carrier.

5030.

(New) An immunogenic composition comprising,

- (a) An immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment consists of a receptor binding domain of vascular endothelial growth factor, and immunogenic fragments of said immunogenic peptide
- (b) wherein the immunogenic peptide fragment consists of SEQ ID NO: 6; and
- (c) a pharmaceutically acceptable carrier.
-

Amendments to the Claims

(Marked up version)

5. (Thrice Amended) An immunogenic composition comprising,
- (a) an immunogenic peptide fragment of fibroblast growth factor wherein the immunogenic peptide consists of a heparin binding domain of fibroblast growth factor, and immunogenic fragments of said immunogenic peptide[thereof]; and
 - (b) a pharmaceutically acceptable carrier.
15. (Thrice Amended) An immunogenic composition comprising,
- (a) an immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment consists of a receptor binding domain of vascular endothelial growth factor, and immunogenic fragments of said immunogenic peptide[thereof]
 - (b) wherein the immunogenic peptide fragment consists of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9; and
 - (c) a pharmaceutically acceptable carrier.
25. (Thrice Amended) An immunogenic composition comprising,
- (a) an immunogenic peptide fragment of fibroblast growth factor and vascular endothelial growth factor, wherein the immunogenic peptide fragment of fibroblast growth factor consists of a heparin binding domain and immunogenic fragments of said immunogenic peptide[thereof], and wherein the immunogenic peptide fragment of vascular endothelial growth factor consists of a receptor binding domain and immunogenic fragments of said immunogenic peptide[thereof]; and

- (b) a pharmaceutically acceptable carrier.
30. (New) An immunogenic composition comprising,
- (a) An immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment consists of a receptor binding domain of vascular endothelial growth factor, and immunogenic fragments of said immunogenic peptide
 - (b) wherein the immunogenic peptide fragment consists of SEQ ID NO: 6; and
 - (c) a pharmaceutically acceptable carrier.